It’s only fair to share… Ciltacabtagene autoleucel FDA APPROVED, 2022/2/28, Carvykti Treatment of multiple myeloma JNJ-68284528 LCAR-B38M CAR-T cells Ciltacabtagene autoleucel is a BCMA-directed CAR T-cell therapy used in the treatment of relapsed or refractory multiple myeloma in previously treated patients. U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T …